Stable gastric pentadecapeptide BPC 157 and bupivacaine

Area of Science:

• Cardiology
• Pharmacology
• Toxicology

Background:

• Bupivacaine overdose can lead to severe cardiotoxicity with no effective therapeutic solution.
• BPC 157, a stable gastric pentadecapeptide, has demonstrated protective effects against various toxic insults and arrhythmias.
• Previous studies suggest BPC 157 has a favorable safety profile with no known toxicity.

Purpose of the Study:

• To investigate the efficacy of BPC 157 as a potential antidote for bupivacaine-induced cardiotoxicity.
• To evaluate the protective effects of BPC 157 against bupivacaine toxicity in vivo in rats and in vitro in HEK293 cells.

Main Methods:

• Rats were injected with bupivacaine (100mg/kg IP) and treated with varying doses of BPC 157 at different time points.
• Cardiovascular parameters (bradycardia, AV-block, ventricular arrhythmias, QRS duration) and survival rates were monitored.
• HEK293 cells were used to assess the effect of bupivacaine and BPC 157 on cell membrane potential (Vm).

Main Results:

• BPC 157 administration significantly counteracted bupivacaine-induced cardiotoxicity, including bradycardia, AV-block, ventricular arrhythmias, and T-wave elevation.
• Survival rates were improved in rats treated with BPC 157, even when administered shortly after bupivacaine.
• In vitro, BPC 157 inhibited bupivacaine-induced cell membrane depolarization in HEK293 cells.

Conclusions:

• BPC 157 demonstrates significant potential as an antidote for bupivacaine cardiotoxicity.
• The findings suggest BPC 157 can prevent and reverse severe cardiac events associated with bupivacaine overdose.
• BPC 157's ability to counteract bupivacaine-induced depolarization warrants further investigation for clinical application.